Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 2, 2015
- Accepted in final form February 1, 2016
- First Published April 20, 2016.
Author Disclosures
- Petra Bergman, PhD,
- Eliane Piket,
- Mohsen Khademi, PhD,
- Tojo James,
- Lou Brundin, MD, PhD,
- Tomas Olsson, MD, PhD,
- Fredrik Piehl, MD, PhD and
- Maja Jagodic, PhD
- Petra Bergman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eliane Piket,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mohsen Khademi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tojo James,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lou Brundin, MD, PhD,
Advisory board Genzyme Advisory board Biogen
NONE
ECTRIMS summer school teaching Speaker honoraria from Biogen and Genzyme
Information written for the Swedish MPA on MS treatment
NONE
Chapter on spinal cord injury in the Swedish Brain Fund book
NONE
NONE
NONE
Participated in an airline commercial (SAS)
NONE
NONE
Swedish MRC K2013-62X-20724-06-3 Karolinska Institutet Stockholm County
NONE
Soderberg Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Tomas Olsson, MD, PhD,
scientific advisory boards: Merck-Serono 2008-2010, BiogenIdec 2006- 2014 and Genzyme/SanofiAventis 2006-2014, Novartis 2009-2014. With all of them advice with regard to therapy in multiple sclerosis
NONE
For lectures on Multiple sclerosis, Novartis 2008 and BiogenIdec 2006, 2007, 2008, 2009, 2010 , 2011 and 2012. SanofiAventis and Merck 2010, Genzyme 2012 and 2013.Medimmune 2013
Co-editor 2006 in Current opinion in Immunology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1)Merck, 2)BiogenIdec, 3)SanofiAventis, 4)Bayer, 5) Novartis,6)AstraZeneca
Tomas Olsson (TO) has received grant support from The Swedish Research council (07488), EU fp7, Euratrans Neurinox 2012-2015 and combiMS, 2013-2014, Swedish Brain foundation,the AFA foundation, Knut and Alice Wallenberg foundation.
NONE
The Knut and Allice Wallenberg foundation, The Swedish Brain foundation, the AFA foundation, EU FP 7 Neurinox and EURATrans projects.TO has also received unrestricted research grants from Bayer Schering, Genzyme/Sanofi-AventisBiogen Idec and AstraZeneca.
NONE
NONE
NONE
NONE
NONE
NONE
- Fredrik Piehl, MD, PhD and
data safety monitoring committee Parexel/Chugai
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Biogen - unrestricted academic research projects outside of this study 2. Novartis - unrestricted academic research projects outside of this study 3. Genzyme - unrestricted academic research projects outside of this study
Swedish Medical Research Council (grant 2014-3077) PI, 2013-ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maja Jagodic, PhD
NONE
NONE
NONE
(1) Physiological Genomics, Editorial Board member, 2015-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) AstraZeneca (AstraZeneca-Science for Life Laboratory collaboration), co-investigator, 2014-2017
(1) The Swedish Research Council, lead investigator, K2015-61X-20776-08-3, 2015-2018 (2) The Swedish Research Council, lead investigator, K2012-99X-20776-05-3, 2012-2014 (3) The regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, lead investigator, 2014-2015
NONE
(1) The Swedish Association for Persons with Neurological Disabilities, co-investigator (2) The Swedish Brain Foundation, main investigator (3) The Swedish Medical Society, main investigator (4) Petrus and Augusta Hedlunds Foundation, main investigator
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
- Correspondence to Dr. Jagodic: maja.jagodic{at}ki.se
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Article
Natalizumab in progressive MSResults of an open-label, phase 2A, proof-of-concept trialJeppe Romme Christensen, Rikke Ratzer, Lars Börnsen et al.Neurology, March 28, 2014 -
Articles
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MSF. Sellebjerg, L. Börnsen, M. Khademi et al.Neurology, December 07, 2009 -
Article
Identification of MS-specific serum miRNAs in an international multicenter studyKeren Regev, Brian C. Healy, Anu Paul et al.Neurology: Neuroimmunology & Neuroinflammation, August 20, 2018